Skip to main content
Top
Published in: BMC Nephrology 1/2021

Open Access 01-12-2021 | Arteriography | Research article

Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention

Authors: H. Zhang, H. Fu, X. Fu, J. Zhang, P. Zhang, S. Yang, Z. Zeng, N. Fu, Z. Guo

Published in: BMC Nephrology | Issue 1/2021

Login to get access

Abstract

Backgrounds

Diabetes mellitus is an independent risk factor for Contrast-induced nephropathy (CIN) in patients undergoing Coronary arteriography (CAG)/percutaneous coronary intervention (PCI). Glycosylated hemoglobin (HbA1c) is the gold standard to measure blood glucose control, which has important clinical significance for evaluating blood glucose control in diabetic patients in the past 3 months. This study aimed to assess whether preoperative HbA1c levels in diabetic patients who received CAG/PCI impacted the occurrence of postoperative CIN.

Methods

We reviewed the incidence of preoperative HbA1c and postoperative CIN in 670 patients with CAG/PCI from January 1, 2020 to October 30, 2020 and divided the preoperative HbA1c levels into 5 groups. Blood samples were collected at admission, 48 h and 72 h after operation to measure the Scr value of patients. Categorical variables were compared using a chi-square test, and continuous variables were compared using an analysis of variance. Fisher’s exact test was used to compare the percentages when the expected frequency was less than 5. Univariable and multivariable logistic regression analysis was used to exclude the influence of confounding factors, and P for trend was used to analyze the trend between HbA1c levels and the increased risk of CIN.

Results

Patients with elevated HbA1c had higher BMI, FBG, and LDL-C, and they were more often on therapy with hypoglycemic agents, Insulin and PCI. They also had higher basal, 48 h and 72 h Scr. The incidence of CIN in the 5 groups of patients were: 9.8, 11.9, 15.2, 25.3, 48.1%. (p < 0.0001) The multivariate analysis confirmed that in the main high-risk subgroup, patients with elevated HbA1C levels (≥8.8%) had a higher risk of CIN disease. Trend test showed the change of OR (1.000,1.248,1.553,2.625,5.829).

Conclusions

Studies have shown that in diabetic patients undergoing CAG/PCI, elevated HbA1c is independently associated with the risk of CIN, and when HbA1c > 9.5%, the incidence of CIN trends increase. Therefore, we should attach great importance to patients with elevated HbA1c at admission and take more active measures to prevent CIN.
Literature
1.
go back to reference Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, Heretis I, Wilks MF, Spandidos DA, et al. Contrast-induced nephropathy: Basic concepts, pathophysiological implications and prevention strategies. Pharmacol Ther. 2017;180:99–112 2017-12-01.CrossRef Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, Heretis I, Wilks MF, Spandidos DA, et al. Contrast-induced nephropathy: Basic concepts, pathophysiological implications and prevention strategies. Pharmacol Ther. 2017;180:99–112 2017-12-01.CrossRef
2.
go back to reference Mehran R, Nikolsky E. Contrast-induced nephropathy: Definition, epidemiology, and patients at risk. Kidney Int. 2006;69:S11–5 2006-01-01.CrossRef Mehran R, Nikolsky E. Contrast-induced nephropathy: Definition, epidemiology, and patients at risk. Kidney Int. 2006;69:S11–5 2006-01-01.CrossRef
5.
go back to reference Liu Y, Tan N, Zhou YL, Chen YY, Chen JY, Chen J, et al. High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention. J Nephrol. 2012;25(3):332–40 2012-05-01.CrossRef Liu Y, Tan N, Zhou YL, Chen YY, Chen JY, Chen J, et al. High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention. J Nephrol. 2012;25(3):332–40 2012-05-01.CrossRef
6.
go back to reference Lau A, Chung H, Komada T, Platnich JM, Sandall CF, Choudhury SR, et al. Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury. J Clin Invest. 2018;128(7):2894–913 2018-07-02.CrossRef Lau A, Chung H, Komada T, Platnich JM, Sandall CF, Choudhury SR, et al. Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury. J Clin Invest. 2018;128(7):2894–913 2018-07-02.CrossRef
7.
go back to reference Qin Y, Yan G, Ma C, Tang C, Ma G. Effects of hyperglycaemia and elevated glycosylated haemoglobin on contrast-induced nephropathy after coronary angiography. Exp Ther Med. 2018;16(1):377–83 2018-01-01.PubMedPubMedCentral Qin Y, Yan G, Ma C, Tang C, Ma G. Effects of hyperglycaemia and elevated glycosylated haemoglobin on contrast-induced nephropathy after coronary angiography. Exp Ther Med. 2018;16(1):377–83 2018-01-01.PubMedPubMedCentral
8.
go back to reference Chen Y, Fu N, Xu J, Yang S, Li S, Liu Y, et al. A simple preprocedural score for risk of contrast-induced acute kidney injury after percutaneous coronary intervention. Catheter Cardio Int. 2014;83(1):E8–16 2014-01-01.CrossRef Chen Y, Fu N, Xu J, Yang S, Li S, Liu Y, et al. A simple preprocedural score for risk of contrast-induced acute kidney injury after percutaneous coronary intervention. Catheter Cardio Int. 2014;83(1):E8–16 2014-01-01.CrossRef
9.
go back to reference Toprak O, Cirit M, Yesil M, Bayata S, Tanrisev M, Varol U, et al. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. Nephrol Dial Transplant. 2007;22(3):819–26 2007-01-05.CrossRef Toprak O, Cirit M, Yesil M, Bayata S, Tanrisev M, Varol U, et al. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. Nephrol Dial Transplant. 2007;22(3):819–26 2007-01-05.CrossRef
11.
go back to reference Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008;117(12):1610–9 2008-03-25.CrossRef Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008;117(12):1610–9 2008-03-25.CrossRef
14.
go back to reference American Diabetes Association. Classification and diagnosis of diabetes:standards of medical care in diabetes—2018. Diabetes Care. 2017;41(Supplement 1):S13–27.CrossRef American Diabetes Association. Classification and diagnosis of diabetes:standards of medical care in diabetes—2018. Diabetes Care. 2017;41(Supplement 1):S13–27.CrossRef
15.
go back to reference Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160–7 2003-11-01.CrossRef Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160–7 2003-11-01.CrossRef
16.
go back to reference Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017;389(10076):1312–22 2017-04-01.CrossRef Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017;389(10076):1312–22 2017-04-01.CrossRef
17.
go back to reference Fu H, Zhang J, Zhang H, Zhang P, Fu X, Zeng Z, et al. Trimetazidine can prevent the occurrence of contrast-induced nephropathy after percutaneous coronary intervention in elderly patients with renal insufficiency. Perfusion. 2020:267659120957856. https://doi.org/10.1177/0267659120957856. Epub ahead of print. Fu H, Zhang J, Zhang H, Zhang P, Fu X, Zeng Z, et al. Trimetazidine can prevent the occurrence of contrast-induced nephropathy after percutaneous coronary intervention in elderly patients with renal insufficiency. Perfusion. 2020:267659120957856. https://​doi.​org/​10.​1177/​0267659120957856​. Epub ahead of print.
18.
go back to reference Deek H, Newton P, Sheerin N, Noureddine S, Davidson PM. Contrast media induced nephropathy: a literature review of the available evidence and recommendations for practice. Aust Crit Care. 2014;27(4):166–71 2014-11-01.CrossRef Deek H, Newton P, Sheerin N, Noureddine S, Davidson PM. Contrast media induced nephropathy: a literature review of the available evidence and recommendations for practice. Aust Crit Care. 2014;27(4):166–71 2014-11-01.CrossRef
19.
go back to reference Wang YC, Tang A, Chang D, Lu CQ, Zhang SJ, Ju S. Long-term adverse effects of low-Osmolar compared with Iso-Osmolar contrast media after coronary Angiography. Am J Cardiol. 2016;118(7):985–90 2016-10-01.CrossRef Wang YC, Tang A, Chang D, Lu CQ, Zhang SJ, Ju S. Long-term adverse effects of low-Osmolar compared with Iso-Osmolar contrast media after coronary Angiography. Am J Cardiol. 2016;118(7):985–90 2016-10-01.CrossRef
20.
go back to reference Cheng W, Zhao F, Tang CY, Li XW, Luo M, Duan SB. Comparison of iohexol and iodixanol induced nephrotoxicity, mitochondrial damage and mitophagy in a new contrast-induced acute kidney injury rat model. Arch Toxicol. 2018;92(7):2245–57 2018-07-01.CrossRef Cheng W, Zhao F, Tang CY, Li XW, Luo M, Duan SB. Comparison of iohexol and iodixanol induced nephrotoxicity, mitochondrial damage and mitophagy in a new contrast-induced acute kidney injury rat model. Arch Toxicol. 2018;92(7):2245–57 2018-07-01.CrossRef
21.
go back to reference Lubbers MM, Kock M, Niezen A, Galema T, Kofflard M, Bruning T, et al. Iodixanol versus Iopromide at Coronary CT Angiography: Lumen Opacification and effect on Heart Rhythm-the Randomized IsoCOR Trial. Radiology. 2018;286(1):71–80 2018-01-01.CrossRef Lubbers MM, Kock M, Niezen A, Galema T, Kofflard M, Bruning T, et al. Iodixanol versus Iopromide at Coronary CT Angiography: Lumen Opacification and effect on Heart Rhythm-the Randomized IsoCOR Trial. Radiology. 2018;286(1):71–80 2018-01-01.CrossRef
22.
go back to reference Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol. 2008;3(3):844–61 2008-01-01.CrossRef Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol. 2008;3(3):844–61 2008-01-01.CrossRef
23.
go back to reference Bhatt DL. Percutaneous Coronary Intervention in 2018. JAMA. 2018;319(20):2127–8 2018-05-22.CrossRef Bhatt DL. Percutaneous Coronary Intervention in 2018. JAMA. 2018;319(20):2127–8 2018-05-22.CrossRef
24.
go back to reference Hussien NI, Sorour SM, El-kerdasy HI, Abdelrahman BA. The glucagon-like peptide-1 receptor agonist Exendin-4, ameliorates contrast-induced nephropathy through suppression of oxidative stress, vascular dysfunction and apoptosis independent of glycaemia. Clin Exp Pharmacol P. 2018;45(8):808–18. https://doi.org/10.1111/1440-1681.12944.CrossRef Hussien NI, Sorour SM, El-kerdasy HI, Abdelrahman BA. The glucagon-like peptide-1 receptor agonist Exendin-4, ameliorates contrast-induced nephropathy through suppression of oxidative stress, vascular dysfunction and apoptosis independent of glycaemia. Clin Exp Pharmacol P. 2018;45(8):808–18. https://​doi.​org/​10.​1111/​1440-1681.​12944.CrossRef
26.
go back to reference Gabbay KH. Glycosylated hemoglobin and diabetes mellitus. Med Clin North Am. 1982;66(6):1309–15 1982-11-01.CrossRef Gabbay KH. Glycosylated hemoglobin and diabetes mellitus. Med Clin North Am. 1982;66(6):1309–15 1982-11-01.CrossRef
27.
go back to reference Naito R, Miyauchi K. Coronary Artery Disease and Type 2 Diabetes Mellitus. Int Heart J. 2017;58(4):475–80 2017-08-03.CrossRef Naito R, Miyauchi K. Coronary Artery Disease and Type 2 Diabetes Mellitus. Int Heart J. 2017;58(4):475–80 2017-08-03.CrossRef
29.
go back to reference Cakmak M, Cakmak N, Cetemen S, Tanriverdi H, Enc Y, Teskin O, et al. The value of admission glycosylated hemoglobin level in patients with acute myocardial infarction. Can J Cardiol. 2008;24(5):375–8 2008-05-01.CrossRef Cakmak M, Cakmak N, Cetemen S, Tanriverdi H, Enc Y, Teskin O, et al. The value of admission glycosylated hemoglobin level in patients with acute myocardial infarction. Can J Cardiol. 2008;24(5):375–8 2008-05-01.CrossRef
Metadata
Title
Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention
Authors
H. Zhang
H. Fu
X. Fu
J. Zhang
P. Zhang
S. Yang
Z. Zeng
N. Fu
Z. Guo
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2021
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-021-02405-y

Other articles of this Issue 1/2021

BMC Nephrology 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.